Publication date: 28 September 2017
Source:Cancer Letters, Volume 404
Author(s): Leslie Calapre, Lydia Warburton, Michael Millward, Mel Ziman, Elin S. Gray
Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy. This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings.
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader http://ift.tt/2tWzCtO
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174